CoChat

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction

Open access
Cunningham, Lea, Finckbeiner, Steven, Hyde, R. Katherine, Southall, Noel, Marugan, Juan, Yedavalli, Venkat R. K., Dehdashti, Seameen Jean, Reinhold, William C., Alemu, Lemlem, Zhao, Ling, Yeh, Jing-Ruey Joanna, Sood, Raman, Pommier, Yves, Austin, Christopher P., Jeang, Kuan-Teh, Zheng, Wei, Liu, Paul · 2012 · Proceedings of the National Academy of Sciences
Cited by 137

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Core binding factor (CBF) leukemias, those with translocations or inversions that affect transcription factor genes RUNX1 or CBFB , account for ∼24% of adult acute myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL). Current treatments for CBF leukemias are associated with significant morbidity and mortality, with a 5-y survival rate of ∼50%. We hypothesize that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. We developed high-throughput AlphaScreen and time-resolved fluorescence resonance energy transfer (TR-FRET) methods to quantify the RUNX1–CBFβ interaction and screen a library collection of 243,398 compounds. Ro5-3335, a benzodiazepine identified from the screen, was able to interact with RUNX1 and CBFβ directly, repress RUNX1/CBFB -dependent transactivation in reporter assays, and repress runx1 -dependent hematopoiesis in zebrafish embryos. Ro5-3335 preferentially killed human CBF leukemia cell lines, rescued preleukemic phenotype in a RUNX1–ETO transgenic zebrafish, and reduced leukemia burden in a mouse CBFB–MYH11 leukemia model. Our data thus confirmed that RUNX1–CBFβ interaction can be targeted for leukemia treatment and we have identified a promising lead compound for this purpose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1200037109

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 137

Metadata

Authors
Cunningham, L., Finckbeiner, S., Hyde, R. K., Southall, N., Marugan, J., Yedavalli, V. R. K., Dehdashti, S. J., Reinhold, W. C., Alemu, L., Zhao, L., Yeh, J.-R. J., Sood, R., Pommier, Y., Austin, C. P., Jeang, K.-T., Zheng, W., & Liu, P.
Venue
Proceedings of the National Academy of Sciences
Published
2012-08-21
Volume
109
Issue
36
Pages
14592-14597
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2064054876
Cited by
137
References
10
FWCI
4.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction. https://app.cochat.ai/papers/10.1073/pnas.1200037109
The paper
Cunningham, L., Finckbeiner, S., Hyde, R. K., Southall, N., Marugan, J., Yedavalli, V. R. K., Dehdashti, S. J., Reinhold, W. C., Alemu, L., Zhao, L., Yeh, J.-R. J., Sood, R., Pommier, Y., Austin, C. P., Jeang, K.-T., Zheng, W., & Liu, P. (2012). Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1200037109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.